The pharmacy discovered an impurity called dimethylformamide, which is classified as a probable carcinogen by the World Health Organization.
The impurity was found in valsartan manufactured by five companies, including Novartis. The online pharmacy recommended a recall.
The FDA will evaluate Valisure’s findings.
Dozens of forms of generic valsartan have been recalled since July 2018, after an impurity known as N-Nitrosodimethylamine was detected in a version of the drug.
Dimethylformamide is the fourth potential carcinogen to be found in generic versions of the heart pills.
More articles on pharmacy:
Lupin recalls 18,408 bottles of antibiotic in US
Bluebird Bio prices gene therapy at $1.8M
10 hospitals seeking pharmacy leaders
